Eli Lilly said on Thursday its experimental pill, orforglipron, led to a weight loss of nearly 8% at the highest dose and ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with ...

By December 2023, 12.3% of all glucose-lowering medication dispensations were tirzepatide among adults with T2DM.

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in ...

Tirzepatide and GLP-1 receptor agonists are replacing older treatments, marking a shift in how diabetes and weight loss are ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

“Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be sustained for up to three years,” Dr. Busetto noted. He added, “Regardless of age, BMI, and ...